1. Home
  2. INFY vs ARGX Comparison

INFY vs ARGX Comparison

Compare INFY & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Infosys Limited

INFY

Infosys Limited

HOLD

Current Price

$12.77

Market Cap

49.5B

Sector

Technology

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$785.64

Market Cap

42.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INFY
ARGX
Founded
1981
2008
Country
India
Netherlands
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.5B
42.9B
IPO Year
1999
2017

Fundamental Metrics

Financial Performance
Metric
INFY
ARGX
Price
$12.77
$785.64
Analyst Decision
Hold
Strong Buy
Analyst Count
5
19
Target Price
$14.60
$1,008.56
AVG Volume (30 Days)
15.7M
268.8K
Earning Date
04-23-2026
05-07-2026
Dividend Yield
3.56%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.87
$44.39
Revenue Next Year
$6.67
$20.84
P/E Ratio
$19.11
$33.69
Revenue Growth
N/A
N/A
52 Week Low
$12.16
$510.06
52 Week High
$30.00
$934.62

Technical Indicators

Market Signals
Indicator
INFY
ARGX
Relative Strength Index (RSI) 43.84 49.52
Support Level $12.65 $758.42
Resistance Level $14.57 $855.57
Average True Range (ATR) 0.36 21.23
MACD -0.01 -2.81
Stochastic Oscillator 28.95 33.88

Price Performance

Historical Comparison
INFY
ARGX

About INFY Infosys Limited

Infosys is an IT services provider based in Bengaluru, India, with offices in more than 50 countries. The company leverages its offshore outsourcing model to serve clients across different industries, such as financial services and manufacturing. Infosys' IT services offerings include consulting, digital transformation, and business process outsourcing.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: